IL136515A0 - Combination effective for the treatment of impotence - Google Patents

Combination effective for the treatment of impotence

Info

Publication number
IL136515A0
IL136515A0 IL13651598A IL13651598A IL136515A0 IL 136515 A0 IL136515 A0 IL 136515A0 IL 13651598 A IL13651598 A IL 13651598A IL 13651598 A IL13651598 A IL 13651598A IL 136515 A0 IL136515 A0 IL 136515A0
Authority
IL
Israel
Prior art keywords
impotence
treatment
combination effective
effective
combination
Prior art date
Application number
IL13651598A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22090927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL136515(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL136515A0 publication Critical patent/IL136515A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IL13651598A 1997-12-16 1998-10-29 Combination effective for the treatment of impotence IL136515A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6974197P 1997-12-16 1997-12-16
PCT/IB1998/001723 WO1999030697A2 (fr) 1997-12-16 1998-10-29 Composition efficace pour le traitement de l'impuissance

Publications (1)

Publication Number Publication Date
IL136515A0 true IL136515A0 (en) 2001-06-14

Family

ID=22090927

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13651598A IL136515A0 (en) 1997-12-16 1998-10-29 Combination effective for the treatment of impotence

Country Status (37)

Country Link
EP (1) EP1037616B1 (fr)
JP (2) JP2002508315A (fr)
KR (1) KR20010033092A (fr)
CN (1) CN1282248A (fr)
AP (1) AP915A (fr)
AR (1) AR016433A1 (fr)
AT (1) ATE318602T1 (fr)
AU (1) AU759825B2 (fr)
BG (1) BG104528A (fr)
BR (1) BR9813699A (fr)
CA (1) CA2314993A1 (fr)
CO (1) CO4810381A1 (fr)
CZ (1) CZ20002199A3 (fr)
DE (1) DE69833671T2 (fr)
DZ (1) DZ2675A1 (fr)
EA (1) EA200000526A1 (fr)
ES (1) ES2258300T3 (fr)
GT (1) GT199800177A (fr)
HN (1) HN1998000174A (fr)
HR (1) HRP20000407A2 (fr)
HU (1) HUP0100705A3 (fr)
IL (1) IL136515A0 (fr)
IS (1) IS5504A (fr)
MA (1) MA26586A1 (fr)
NO (1) NO20003065L (fr)
NZ (1) NZ504487A (fr)
OA (1) OA11423A (fr)
PA (1) PA8462801A1 (fr)
PE (1) PE20000011A1 (fr)
PL (1) PL341575A1 (fr)
SK (1) SK8782000A3 (fr)
TN (1) TNSN98227A1 (fr)
TR (1) TR200001733T2 (fr)
UY (1) UY25300A1 (fr)
WO (1) WO1999030697A2 (fr)
YU (1) YU33700A (fr)
ZA (1) ZA9811507B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
DE19844162A1 (de) * 1998-09-25 2000-03-30 Udo Dunzendorfer Medikamentenkombinationen zur Therapie der erektilen Dysfunktion
AU3724400A (en) * 1999-03-08 2000-09-28 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
KR20060093355A (ko) * 1999-08-03 2006-08-24 릴리 아이코스 엘엘씨 베타-카르볼린 약학 조성물
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
WO2002022127A1 (fr) * 2000-09-13 2002-03-21 Isis Innovation Limited Utilisation d"inhibiteurs de phosphodiesterase pour le traitement de trouble ano-rectal
WO2002040008A2 (fr) * 2000-11-17 2002-05-23 Warner-Lambert Company Llc Traitement de dysfonctionnements sexuels
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2451267A1 (fr) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
NZ568694A (en) 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
WO2008095136A2 (fr) 2007-01-31 2008-08-07 Henkin Robert I Procédés de détection de substances biologiques
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
CN101781302B (zh) * 2009-05-31 2013-07-10 段波 一种磷酸二酯酶抑制剂和异黄酮形成的加成物及其应用
EP2804603A1 (fr) 2012-01-10 2014-11-26 President and Fellows of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
WO2014055801A1 (fr) 2012-10-05 2014-04-10 Henkin Robert I Inhibiteurs de la phosphodiestérase destinés à traiter des troubles du goût et de l'odorat
CN106233141B (zh) 2014-02-18 2018-08-21 罗伯特·I·汉金 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA878182B (en) * 1986-11-05 1988-05-02 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
EP0459666B1 (fr) * 1990-05-31 1994-11-09 Pfizer Inc. Médicament contre l'impuissance
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
AU9455898A (en) 1999-07-05
CO4810381A1 (es) 1999-06-30
EP1037616A2 (fr) 2000-09-27
TNSN98227A1 (fr) 2005-03-15
PE20000011A1 (es) 2000-01-18
DE69833671T2 (de) 2006-11-30
IS5504A (is) 2000-05-19
WO1999030697A2 (fr) 1999-06-24
KR20010033092A (ko) 2001-04-25
HN1998000174A (es) 1999-01-08
CN1282248A (zh) 2001-01-31
EP1037616B1 (fr) 2006-03-01
ZA9811507B (en) 2000-06-19
HUP0100705A3 (en) 2001-12-28
PA8462801A1 (es) 2000-05-24
DE69833671D1 (de) 2006-04-27
GT199800177A (es) 2000-05-02
BR9813699A (pt) 2000-10-10
ES2258300T3 (es) 2006-08-16
AP9801414A0 (en) 1998-12-31
JP2002508315A (ja) 2002-03-19
YU33700A (sh) 2004-05-12
TR200001733T2 (tr) 2000-11-21
NO20003065L (no) 2000-08-15
EA200000526A1 (ru) 2000-12-25
HRP20000407A2 (en) 2000-10-31
AR016433A1 (es) 2001-07-04
DZ2675A1 (fr) 2003-03-29
MA26586A1 (fr) 2004-12-20
WO1999030697A3 (fr) 1999-08-26
JP2007332156A (ja) 2007-12-27
SK8782000A3 (en) 2002-03-05
BG104528A (en) 2001-02-28
NZ504487A (en) 2002-11-26
UY25300A1 (es) 2000-12-29
AP915A (en) 2000-12-18
NO20003065D0 (no) 2000-06-15
OA11423A (en) 2004-04-21
ATE318602T1 (de) 2006-03-15
CA2314993A1 (fr) 1999-06-24
CZ20002199A3 (cs) 2001-10-17
HUP0100705A2 (hu) 2001-08-28
PL341575A1 (en) 2001-04-23
AU759825B2 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
HUP0100705A3 (en) Combination effective for the treatment of impotence
GB2321719B (en) Liquid treatment
GB9411080D0 (en) Treatment
GB2322568B (en) Gas treatment devices
GB9700899D0 (en) Novel treatment
GB9725114D0 (en) Treatment of pruritus
IL130831A0 (en) Imino-aza-anthracylinone derivatives for the treatment of amyloidosis
IL135994A0 (en) Combination therapy for the treatment of aids
GB9416410D0 (en) Effluent treatment
GB9811525D0 (en) Sewage treatment
GB9726223D0 (en) The treatment of materials
GB2331514B (en) Effluent treatment
GB2286716B (en) The treatment of solid wastes
GB9721692D0 (en) Novel treatment
GB9716742D0 (en) Treatment
SI1068199T1 (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression
ZA988304B (en) The treatment of liquids
IL121227A0 (en) Composition for the treatment of seborrhea
GB9711583D0 (en) Sewage treatment
GB9701448D0 (en) Methods of treatment
GB9721693D0 (en) Novel treatment
GB9711584D0 (en) Activated sludge treatment
ZA9810306B (en) Combination therapy for the treatment of aids
ZA9811524B (en) Treatment of effluent
GB9713581D0 (en) Treatment of neuropsychiatric disorders